ALTSTATION.IO

McKesson Corporation (MCK) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$938.62

Change

-2.00%

Market Cap

$115.85B

Avg Volume

723.8K

Company Overview

McKesson Corporation, headquartered in Irving, Texas, is a leading player in the healthcare sector, specializing in medical distribution. The company operates through four main segments: U.S. Pharmaceutical, Prescription Technology Solutions, Medical-Surgical Solutions, and International. It distributes a wide range of pharmaceutical products, including branded, generic, and specialty drugs, while also providing healthcare-related solutions to hospitals, pharmacies, and community practices. Their services include logistics, practice management, and clinical support to ensure that healthcare providers can deliver effective patient care.

McKesson holds a strong competitive position as a market leader in the healthcare distribution space. Its vast network and established relationships with manufacturers and healthcare providers give it a significant edge over competitors like Cardinal Health and AmerisourceBergen. However, the company faces threats from rising operational costs and regulatory challenges that could impact profit margins. The healthcare landscape is also increasingly moving toward value-based care, which may require McKesson to adapt its business model and service offerings accordingly.

Currently, McKesson is focused on growth and innovation, actively pivoting to meet changing market demands. The company has made strategic investments in technology, notably through its Prescription Technology Solutions segment, to enhance patient access to medications and streamline distribution processes. Additionally, McKesson recently reported a revenue increase of 10% year-over-year, indicating solid demand for its services and reinforcing its market position. These developments set a positive context for evaluating its future performance prospective.

Key Financials

Market Cap

$115.85B

Revenue

$397.96B

EBITDA

$5.93B

Gross Margin

3.5%

Profit Margin

1.1%

Revenue Growth

11.4%

Total Cash

$2.96B

Total Debt

$8.73B

Free Cash Flow

$9.16B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

27.07

Forward P/E

21.27

Beta

0.41

52-Week High

$971.93

52-Week Low

$583.55

EPS

$34.67

50-Day Avg

$830.40

200-Day Avg

$757.34

Price/Book

-88.94

Technical Analysis

The 52-week chart for McKesson Corporation (MCK) shows a strong upward trend, reflecting a 57.9% increase from the previous year’s price levels. Key support can be identified at the $600 level, which has provided a solid base throughout the year. Resistance is currently observed at $948.68, which is a recent high that the price has struggled to break. Over the last few weeks, momentum has accelerated, especially with the recent spike approaching this resistance level. Currently, at $938.62, the price is just $10.06 away from the peak resistance, indicating a strong bullish sentiment in the market. This positioning near the upper range of the 52-week chart suggests further upward potential, but also heightened risk of a pullback if the resistance level holds.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for McKesson Corporation (MCK) stock in the past week, covering February 1 to February 7, 2026:

Market Update

### McKesson Reports Strong Q3 Fiscal 2026 Results and Raises Full-Year Guidance

Summary:

McKesson announced robust third-quarter results for fiscal year 2026, exceeding analyst expectations for both adjusted earnings per share (EPS) and revenue. The company reported adjusted EPS of $9.34, surpassing the consensus estimate of $9.19, and revenues of $106.2 billion, an 11% increase year-over-year. Following this strong performance, McKesson raised and narrowed its full-year adjusted EPS guidance for fiscal 2026 to a range of $38.80 to $39.20, reflecting confidence in sustained momentum across its core businesses, particularly in oncology and biopharma services.

Market Sentiment and Analyst Recommendations

Bull Case

McKesson just beat Q3 estimates with $9.34 adjusted EPS versus $9.19 consensus and raised full-year guidance to $38.80-$39.20, signaling real operational momentum. Revenue growth of 11.4% on a $397.96B base shows the company is capturing market share in healthcare distribution, a business with structural tailwinds from aging demographics and specialty pharma. The oncology and biopharma services segment is firing on all cylinders, and management’s AI and automation investments are tangible efficiency drivers, not marketing speak. At 27.07x P/E, you’re paying a premium but the company is growing into it with guidance raises and expanding margins. The Medical-Surgical IPO planned for 2027 is a capital allocation story that could unlock value. Analysts have 15 buy ratings with a $963.27 target, implying 2.5% upside from here, but that’s conservative given the momentum and execution track record.

Bear Case

The stock is up 57.9% in 52 weeks and sitting near all-time highs at $938.62, which means most of the good news is priced in. A 27.07x P/E multiple leaves zero margin for error on earnings delivery. The company carries $8.73B in debt against only $2.96B in cash, a 2.95x ratio that limits financial flexibility if healthcare policy shifts or drug pricing pressure accelerates. McKesson’s exit from Europe and the upcoming Medical-Surgical spinoff suggest the core business may not be as attractive as the headline growth suggests. Resistance at $948.68 is right there, and a failed breakout could trigger a sharp pullback given the crowded long positioning. Macro uncertainty around healthcare spending and GLP-1 adoption could compress margins faster than management expects.

What to Watch

Monitor the Medical-Surgical IPO timing and valuation expectations in 2027, as this will reveal whether management thinks the core business deserves the current multiple. Track quarterly gross margin trends in the oncology segment specifically, since that’s the growth story driving the bull case. Watch for any guidance revisions when Q4 earnings hit, especially around adjusted EPS growth rates and free cash flow generation. Pay attention to debt reduction targets and capital allocation priorities now that the European exit is complete. If the stock breaks through $948.68 resistance decisively, the next target is $1,000-$1,012 based on analyst price targets. Conversely, if it rolls over below $920, that signals institutional weakness and could accelerate a retest of $880-$900 support.

Analyst Consensus

BUY

Based on 15 analyst opinions

Low Target

$860.00

Mean Target

$963.27

High Target

$1065.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Distribution

Employees

43,000

Earnings & Dividends

Next Earnings

Feb 04, 2026

EPS (Trailing)

$34.67

Dividend Yield

34.0%

Payout Ratio

8.8%

Frequently Asked Questions

Is MCK a good stock to buy?

Yes, McKesson Corporation has an analyst recommendation of BUY with a target price of $963.27. Given its current price of $938.62, there’s potential upside, making it a strong candidate for investors.

What is MCK’s price target?

The average price target for McKesson is $963.27. This target suggests an upside of about 2.5% from its current price.

Does MCK pay a dividend?

Yes, McKesson has a significant dividend yield of 34.0%. This high yield is attractive for income-focused investors.

What is MCK’s P/E ratio?

McKesson’s P/E ratio stands at 27.07, while the forward P/E is slightly lower at 21.27. These figures indicate that the stock is valued above the market average but may have growth potential.

What has been MCK’s stock performance over the past year?

McKesson’s stock has ranged from $583.55 to $971.93 in the past year. The current price of $938.62 indicates strong performance, hovering near its 52-week high.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.